Radiosensitivity in breast cancer assessed by the histone γ-H2AX and 53BP1 foci

Djuzenova, Cholpon S; Elsner, Ines; Katzer, Astrid; Worschech, Eike; Distel, Luitpold V; Flentje, Michael; Polat, Bülent

doi:10.1186/1748-717X-8-98

Radiation Oncology

Table 2 DNA damage measured by 53BP1 in PBMCs isolated from blood of apparently healthy donors (N) and unselected breast cancer (BC) patients after exposure to 0.5 or 2 Gy of X-irradiation in vitro * or after 5 clinical fractions (BC patients)

From: Radiosensitivity in breast cancer assessed by the histone γ-H2AX and 53BP1 foci

Subject^a	Age (years)	Sex	Clinical status with respect to cancer, skin reaction to RT^b	0 Gy	0.5 Gy, 30’	0.5 Gy, 24 h	2 Gy, 24 h	72 h after 5 clinical fractions
Apparently healthy donors
N-3	29	F	n.d.	0.71	2.47	0.99	1.47
N-4	58	F	n.d.	0.68	2.83	0.96	1.37
N-5	58	F	n.d.	0.41	2.65	1.16	1.25
N-6	65	F	n.d.	0.35	2.48	1.07	1.73
N-7	56	F	n.d.	0.53	2.26	0.66	0.76
N-8	48	F	n.d.	0.38	2.32	0.98	1.36
N-9	41	F	n.d.	0.32	2.10	0.96	1.04
N-10	44	F	n.d.	0.50	2.46	0.79	1.02
N-11	48	F	n.d.	0.48	2.60	0.81	1.20
N-12	43	F	n.d.	0.38	2.42	0.67	0.80
Mean	45			0.47	2.46	0.91	1.20
± SD	12			0.13	0.20	0.16	0.29
Breast cancer patients
BC-01	59	F	BC, grade 3	0.13	0.85	n.d.	1.84	1.73
BC-04	73	F	BC, grade 3	0.15	1.24	n.d.	2.61	1.68
BC-12	61	F	BC, grade 3	0.11	1.19	n.d.	2.18	0.95
BC-13	55	F	BC, grade 3	0.35	2.47	n.d.	2.86	1.23
BC-33	42	F	BC, grade 3	0.35	0.87	n.d.	2.78	1.60
BC-39	55	F	BC, grade 1	0.32	2.56	0.75	1.41	0.90
BC-40	77	F	BC, grade 2	0.61	2.43	0.62	0.61	0.78
BC-41	54	F	BC, grade 1	0.97	2.36	1.11	1.34	0.91
BC-42	49	F	BC, grade 1	0.19	2.48	0.76	1.68	0.80
BC-43	62	F	BC, grade 2	0.33	1.99	0.92	1.58	0.42
BC-44	59	F	BC, grade 1	0.24	2.08	1.25	2.16	0.58
BC-45	51	F	BC, grade 1	0.20	1.73	1.20	2.12	0.77
BC-46	62	F	BC, grade 1	0.33	2.73	1.34	0.56	0.74
BC-47	30	F	BC, grade 2	0.26	2.57	1.38	0.98	0.65
BC-48	71	F	BC, grade 2	0.79	3.34	1.16	1.96	0.93
BC-49	46	F	BC, grade 2	0.49	3.19	1.19	1.84	0.62
BC-50	48	F	BC, grade 3	0.68	3.29	0.88	1.39	0.68
BC-51	57	F	BC, grade 1	0.71	2.82	0.93	1.43	0.50
BC-52	62	F	BC, grade 2	0.66	2.48	0.87	1.50	0.59
BC-53	68	F	BC, grade 2	0.98	2.81	0.84	1.37	0.55
BC-54	37	F	BC, grade 1	0.65	2.29	0.84	1.49	0.95
BC-55	67	F	BC, grade 1	0.73	2.35	0.89	1.50	0.71
BC-57	55	F	BC, grade 1	0.86	3.40	0.89	2.04	0.69
BC-58	62	F	BC, grade 1	0.52	3.25	0.95	2.05	0.57
BC-59	55	F	BC, grade 1	0.45	2.69	0.82	1.62	0.88
BC-60	65	F	BC, grade 2	0.65	2.86	0.97	1.61	0.49
BC-61	54	F	BC, grade 2	0.54	2.66	0.88	1.63	0.96
BC-62	53	F	BC, grade 2	0.49	2.65	0.77	1.37	0.72
BC-63	69	F	BC, grade 1	0.62	2.73	1.05	1.81	0.58
BC-64	81	F	BC, grade 1	0.6	2.62	0.84	1.37	0.47
BC-65	38	F	BC, grade 2	0.58	2.35	0.95	1.70	0.87
BC-66	77	F	BC, grade 1	0.46	2.46	0.83	1.44	0.57
BC-67	48	F	BC, grade 1	0.43	1.87	0.86	1.52	0.66
BC-68	49	F	BC, grade 2	0.42	2.49	0.65	1.73	0.73
BC-69	51	F	BC, grade 1	0.41	2.00	0.84	1.70	0.49
Mean	57			0.49	2.40	0.94	1.70	0.80
± SD	12			0.23	0.63	0.19	0.49	0.32

*Each indicated DNA damage parameter represents the mean value obtained on the cells from a given individual. Bold fonts indicate the unselected BC patients who revealed an adverse acute skin reaction to RT;
^aCase number was according to our files;
^bEarly skin reaction according RTOG score (Cox et al., 1995) [26]. RTOG grade: 1 - follicular, faint or dull erythema, dry desquamation; 2 - tender or bright erythema, moderate edema; 3 - confluent, moist desquamation, pitting edema; 4 - ulceration, haemorrhage, necrosis.
Abbreviations used: N, normal; BC, breast cancer; F, female; n.d. indicates not determined.

Back to article page

ISSN: 1748-717X

Contact us

General enquiries: journalsubmissions@springernature.com